Abiopharma

BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value

Phillips 66 and Kinder Morgan Advance Western Gateway Pipeline Project Following Successful Open Season

NIQ Brandbank and Prodx Unite to Advance Retail Personalization

Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026

Ingles Markets Issues Open Letter to Shareholders

AECOM announces planned dates for second quarter fiscal 2026 earnings results and conference call

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

Blackstone Secured Lending Announces First-Quarter 2026 Earnings Release and Conference Call

FDA Grants Priority Review for KEYTRUDA®(pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer